Talis Announces Pricing of Initial Public Offering
February 11 2021 - 11:39PM
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to
developing innovative molecular diagnostic tests for infectious
diseases at the point-of-care, today announced the pricing of its
initial public offering of 13,800,000 shares of its common stock at
a public offering price of $16.00 per share. The gross proceeds to
Talis from the offering, before deducting underwriting discounts
and commissions and other offering expenses payable by Talis, are
expected to be approximately $220.8 million. In addition, Talis has
granted the underwriters a 30-day option to purchase up to
2,070,000 additional shares of its common stock at the initial
public offering price, less the underwriting discounts and
commissions. All of the shares are being offered by Talis.
Talis has been approved for listing on the Nasdaq
Global Market and is expected to begin trading on Friday, February
12, 2021 under the ticker symbol “TLIS.” The offering is expected
to close on Wednesday, February 17, 2021, subject to customary
closing conditions.
J.P. Morgan, BofA Securities and Piper Sandler
& Co. are acting as book-running managers for the offering.
BTIG is acting as co-manager for the offering.
A registration statement relating to the
securities being sold in this offering was declared effective by
the Securities and Exchange Commission on February 11, 2021. The
offering is made only by means of a prospectus, copies of which may
be obtained, when available, from: J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, by telephone at (866) 803-9204, or by emailing
prospectus-eq_fi@jpmchase.com; BofA Securities, Attention:
Prospectus Department, NC1-004-03-43, 200 North College Street, 3rd
Floor, Charlotte, NC 28255-0001, by telephone at (800) 294-1322, or
by email at dg.prospectus_requests@bofa.com; or Piper Sandler &
Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@psc.com.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Talis
Talis is dedicated to transforming diagnostic
testing by developing and commercializing innovative products that
are designed to enable accurate, low cost and rapid molecular
testing for infectious diseases at the point-of-care. The company
is developing the Talis One platform, a compact, sample-to-answer,
cloud-enabled, molecular diagnostic platform.
Contact: Media & Investors
Emily Faucette efaucette@talisbio.com +1.415.595.9407
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Apr 2023 to Apr 2024